CytoMed Therapeutics (NASDAQ: GDTC) director buys 112,000 shares in open market

Rhea-AI Filing Summary

CytoMed Therapeutics Ltd director and ten percent owner Choo Chee Kong bought 112,000 Ordinary Shares in an open-market purchase at $1.1498 per share. After this transaction, he directly owns 430,324 Ordinary Shares with no derivative positions reported in this filing.

Insider Trade Summary

Net Buyer: 112,000 shares ($128,778)

Net Buy 1 txn

Insider Choo Chee Kong

Role null

Bought 112,000 shs ($129K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares, no par value per share	112,000	$1.1498	$129K

Holdings After Transaction: Ordinary Shares, no par value per share — 430,324 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 112,000 shares Purchase price: $1.1498 per share Shares owned after: 430,324 shares +2 more

5 metrics

Shares purchased 112,000 shares Open-market purchase of Ordinary Shares

Purchase price $1.1498 per share Price paid for Ordinary Shares

Shares owned after 430,324 shares Direct ownership following transaction

Net buy shares 112,000 shares Net buy direction in transaction summary

Buy transactions count 1 transaction Total buy entries in this Form 4

Key Terms

open-market purchase, Ordinary Shares, no par value per share, ten percent owner, non-derivative

4 terms

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Ordinary Shares, no par value per share financial

"security_title: "Ordinary Shares, no par value per share""

ten percent owner financial

"is_ten_percent_owner: 1"

non-derivative financial

"transaction_type: "non-derivative""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Choo Chee Kong

(Last) (First) (Middle)

1 COMMONWEALTH LANE #08-22,

(Street)

SINGAPORE 149544

(City) (State) (Zip)

SINGAPORE

(Country)

2. Issuer Name and Ticker or Trading Symbol
CytoMed Therapeutics Ltd [ GDTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares, no par value per share	05/13/2026	06/08/2026	P		112,000	A	$1.1498	430,324	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Chee Kong Choo	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CytoMed Therapeutics (GDTC) report for Choo Chee Kong?

CytoMed Therapeutics reported that director and ten percent owner Choo Chee Kong made an open-market purchase of 112,000 Ordinary Shares. The shares were acquired in a single transaction classified as a non-derivative equity purchase.

At what price were the GDTC shares purchased by Choo Chee Kong?

Choo Chee Kong purchased the GDTC Ordinary Shares at $1.1498 per share. This price reflects the open-market transaction value reported for the 112,000 shares acquired on the stated transaction date.

How many CytoMed Therapeutics (GDTC) shares does Choo Chee Kong own after the transaction?

Following the reported open-market purchase, Choo Chee Kong directly owns 430,324 Ordinary Shares of CytoMed Therapeutics. This total reflects his holdings after adding the newly purchased 112,000 shares disclosed in the Form 4 filing.

Was the GDTC insider transaction a buy or sell by Choo Chee Kong?

The transaction was a buy, specifically an open-market purchase of Ordinary Shares. The Form 4 classifies it with transaction code P, indicating a purchase in the open market or a private transaction, and no sales were reported.

Did the CytoMed Therapeutics (GDTC) Form 4 include any derivative security activity?

The Form 4 did not report any derivative security transactions for Choo Chee Kong. The filing’s derivative summary is empty, indicating no option exercises, warrant conversions, or other derivative activities in this particular disclosure.